Kerala CM opens Agappe Diagnostics new manufacturing unit  

BL Kochi Bureau Updated - September 12, 2024 at 07:04 PM.
Kerala Chief Minister Pinarayi Vijayan inaugurating state-of-the-art equipment manufacturing facility of Agappe Diagnostics Ltd. Industries Minister P Rajeeve; Benny Behanan, MP; P.V. Srinijin, MLA; Agappe Managing Director Thomas John; APM Mohammed Hanish, Principal Secretary-Industry; S. Harikishore, MD-KSIDC; Adv. C.N. Mohanan, Secretary - CPI(M) Ernakulam; Joseph John, Chairman, Agappe.Takeuchi Shigekez, President & Group CEO, H.U. Group Holdings Inc and  Ishikawa Goki, President & CEO Fujirebio Holdings Inc. also seen.

Kerala Chief Minister Pinarayi Vijayan on Thursday inaugurated the new one lakh sq ft state-of-the-art equipment manufacturing facility of Agappe Diagnostics Ltd., India’s leading In Vitro Diagnostics (IVD) manufacturer at Infopark.

In his address, the Chief Minister underscored the transformative role of Kerala’s industrial sector. Recognized recently as the top State in India for ease of doing business rankings, he said Kerala continues to attract significant investment and innovation.

The Chief Minister also unveiled the first “Make in India” In-Vitro Biomarkers using CLEIA (Chemiluminescent Enzyme Immunoassay) technology, a diagnostic equipment developed by Agappe in partnership with Fujirebio Holdings Inc., Japan.

Agappe, a globally renowned name in diagnostics, marks 29 years of excellence. With products and services utilized by 75,000 customers across 90 countries, Agappe is dedicated to making advanced diagnostic technology accessible to the common man at an affordable cost.

P. Rajeeve, the State Industries Minister, highlighted the achievements of the State’s medical devices industry. Although it constitutes just 6 per cent of the national sector, it contributes a remarkable 20 per cent to the industry’s overall turnover.

This accomplishment is notable given Kerala’s modest size: It represents only 1.2 per cent of the country’s land area and houses 2.8 per cent of its population.

Thomas John, Managing Director of Agappe Diagnostics said the expansion complements Agappe’s existing reagent unit in Pattimattom and its first equipment manufacturing unit at Kinfra, Nellad. The new unit has the potential to boost local employment and provide world-class equipment manufacturing.

The latest diagnostic tools enable the early detection of critical diseases such as Alzheimer’s, cancer, and gastrointestinal disorders. This could significantly slow neurodegeneration in Alzheimer’s patients through medication and lifestyle changes, delaying the onset of the disease.

In the realm of In-Vitro Diagnostics (IVD), CLEIA technology plays a crucial role in screening, early detection, monitoring disease progression, and guiding personalized treatments. Its application in oncology, for instance, can greatly enhance survival rates through early cancer marker detection, Thomas John said.

Published on September 12, 2024 13:34

This is a Premium article available exclusively to our subscribers.

Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

You have reached your free article limit.

Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

You have reached your free article limit.
Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

TheHindu Businessline operates by its editorial values to provide you quality journalism.

This is your last free article.